Treatment Differences Between Adenocarcinoma and Squamous Cell Carcinoma

Lung Cancer Context

The National Comprehensive Cancer Network (NCCN) recommends that all patients with adenocarcinoma must be tested for EGFR mutations and ALK gene rearrangements before initiating systemic therapy, as targeted therapies are potentially very effective in patients with specific gene mutations or rearrangements 1, 2
Additional molecular testing for ROS1, BRAF, MET, and RET should be considered for adenocarcinomas, as these mutations are mutually exclusive and guide targeted therapy selection 3
Testing should be performed on tissue with at least 20-30% tumor cells to minimize false-negative results 3

Squamous cell carcinomas have a greater risk of life-threatening hemorrhage with bevacizumab and should avoid this agent 4, 5
For adenocarcinomas without targetable mutations, platinum-based chemotherapy combined with pemetrexed is preferred 4
For squamous cell carcinomas, platinum-based chemotherapy with agents other than pemetrexed (such as gemcitabine or taxanes) is recommended 4

A minimal panel of p40 and TTF-1 effectively distinguishes squamous cell carcinoma from adenocarcinoma in small biopsy samples 4, 5, 7
Adenocarcinomas are typically TTF-1-positive, napsin A-positive, and p40-negative 4, 5
Squamous cell carcinomas are p40-positive, p63-positive, CK5/6-positive, and TTF-1-negative 4, 5, 7

Squamous cell carcinoma of the esophagus can be treated definitively with chemoradiation without surgery in selected cases, while adenocarcinoma requires surgical resection whenever reasonable 6

The NCCN guidelines recommend never using general NSCLC categories when specific histology can be determined, as this prevents optimal treatment selection 1, 2
Never initiate systemic therapy for adenocarcinoma without completing molecular testing, as this may miss opportunities for highly effective targeted therapy 1, 2
Never use bevacizumab in squamous cell carcinoma due to hemorrhage risk 4
Never assume adenocarcinoma and squamous cell carcinoma respond equivalently to the same treatment regimens—they require histology-specific approaches 4, 5